Home Watchlists Portfolios Indices Forex Futures Crypto Comparisons Alerts Screeners Scans Settings

Vistagen Therapeutics (NASDAQ:VTGN) Given a $4.00 Price Target by Maxim Group Analysts



  • Source: Riverton Roll - - Read: 0

    Summary:

     

    Maxim Group set a $4.00 price objective on Vistagen Therapeutics (NASDAQ:VTGN) in a research note published on Tuesday, October 15th, TipRanks reports. The brokerage currently has a buy rating on the stock.

    Several other equities research analysts have also recently issued reports on VTGN. Chardan Capital reaffirmed a neutral rating on shares of Vistagen Therapeutics in a report on Monday, July 29th. ValuEngine raised Vistagen Therapeutics from a hold rating to a buy rating in a report on Thursday, August 1st. Finally, William Blair reissued a buy rating on shares of Vistagen Therapeutics in a research note on Wednesday, October 9th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock currently has an average rating ...

     

     

    Read Full News: https://rivertonroll.com/news/2019/11/09/maxim-group-reiterates-4-00-price-target-for-vistagen-therapeutics-nasdaqvtgn-updated-updated.html


Log in to reply